Literature DB >> 35995842

Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions.

Zhengzheng Yan1,2, Boxuan Chen1, Yuqiong Yang3, Xinzhu Yi1, Mingyuan Wei1, Gertrude Ecklu-Mensah4, Mary M Buschmann4, Haiyue Liu5, Jingyuan Gao1, Weijie Liang1, Xiaomin Liu1, Junhao Yang1, Wei Ma6, Zhenyu Liang3, Fengyan Wang3, Dandan Chen7, Lingwei Wang7, Weijuan Shi3, Martin R Stampfli8, Pan Li9, Shenhai Gong10, Xia Chen11, Wensheng Shu1, Emad M El-Omar9, Jack A Gilbert4, Martin J Blaser12, Hongwei Zhou13, Rongchang Chen14, Zhang Wang15.   

Abstract

The mechanistic role of the airway microbiome in chronic obstructive pulmonary disease (COPD) remains largely unexplored. We present a landscape of airway microbe-host interactions in COPD through an in-depth profiling of the sputum metagenome, metabolome, host transcriptome and proteome from 99 patients with COPD and 36 healthy individuals in China. Multi-omics data were integrated using sequential mediation analysis, to assess in silico associations of the microbiome with two primary COPD inflammatory endotypes, neutrophilic or eosinophilic inflammation, mediated through microbial metabolic interaction with host gene expression. Hypotheses of microbiome-metabolite-host interaction were identified by leveraging microbial genetic information and established metabolite-human gene pairs. A prominent hypothesis for neutrophil-predominant COPD was altered tryptophan metabolism in airway lactobacilli associated with reduced indole-3-acetic acid (IAA), which was in turn linked to perturbed host interleukin-22 signalling and epithelial cell apoptosis pathways. In vivo and in vitro studies showed that airway microbiome-derived IAA mitigates neutrophilic inflammation, apoptosis, emphysema and lung function decline, via macrophage-epithelial cell cross-talk mediated by interleukin-22. Intranasal inoculation of two airway lactobacilli restored IAA and recapitulated its protective effects in mice. These findings provide the rationale for therapeutically targeting microbe-host interaction in COPD.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35995842     DOI: 10.1038/s41564-022-01196-8

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   30.964


  89 in total

1.  Chronic obstructive pulmonary emphysema; a disease of smokers.

Authors:  W FRANKLIN; F C LOWELL; A L MICHELSON; I W SCHILLER
Journal:  Ann Intern Med       Date:  1956-08       Impact factor: 25.391

2.  Chronic obstructive pulmonary disease: current burden and future projections.

Authors:  A D Lopez; K Shibuya; C Rao; C D Mathers; A L Hansell; L S Held; V Schmid; S Buist
Journal:  Eur Respir J       Date:  2006-02       Impact factor: 16.671

Review 3.  Inflammatory endotypes in COPD.

Authors:  Peter J Barnes
Journal:  Allergy       Date:  2019-03-31       Impact factor: 13.146

Review 4.  Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers.

Authors:  Suresh Garudadri; Prescott G Woodruff
Journal:  Ann Am Thorac Soc       Date:  2018-12

5.  Dysregulated Lung Commensal Bacteria Drive Interleukin-17B Production to Promote Pulmonary Fibrosis through Their Outer Membrane Vesicles.

Authors:  Daping Yang; Xi Chen; Jingjing Wang; Qi Lou; Yunwei Lou; Li Li; Honglin Wang; Jiangye Chen; Meng Wu; Xinyang Song; Youcun Qian
Journal:  Immunity       Date:  2019-02-26       Impact factor: 31.745

6.  Microbiota Promotes Chronic Pulmonary Inflammation by Enhancing IL-17A and Autoantibodies.

Authors:  Koshika Yadava; Céline Pattaroni; Anke K Sichelstiel; Aurélien Trompette; Eva S Gollwitzer; Olawale Salami; Christophe von Garnier; Laurent P Nicod; Benjamin J Marsland
Journal:  Am J Respir Crit Care Med       Date:  2016-05-01       Impact factor: 21.405

7.  Lung microbiome dynamics in COPD exacerbations.

Authors:  Zhang Wang; Mona Bafadhel; Koirobi Haldar; Aaron Spivak; David Mayhew; Bruce E Miller; Ruth Tal-Singer; Sebastian L Johnston; Mohammadali Yavari Ramsheh; Michael R Barer; Christopher E Brightling; James R Brown
Journal:  Eur Respir J       Date:  2016-02-25       Impact factor: 16.671

Review 8.  Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management.

Authors:  Josep Roca; Claudia Vargas; Isaac Cano; Vitaly Selivanov; Esther Barreiro; Dieter Maier; Francesco Falciani; Peter Wagner; Marta Cascante; Judith Garcia-Aymerich; Susana Kalko; Igor De Mas; Jesper Tegnér; Joan Escarrabill; Alvar Agustí; David Gomez-Cabrero
Journal:  J Transl Med       Date:  2014-11-28       Impact factor: 5.531

9.  Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis.

Authors:  Zhang Wang; Nicholas Locantore; Koirobi Haldar; Mohammadali Yavari Ramsheh; Augusta S Beech; Wei Ma; James R Brown; Ruth Tal-Singer; Michael R Barer; Mona Bafadhel; Gavin C Donaldson; Jadwiga A Wedzicha; Dave Singh; Tom M A Wilkinson; Bruce E Miller; Christopher E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 21.405

10.  Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.

Authors:  David Mayhew; Nathalie Devos; Christophe Lambert; James R Brown; Stuart C Clarke; Viktoriya L Kim; Michal Magid-Slav; Bruce E Miller; Kristoffer K Ostridge; Ruchi Patel; Ganesh Sathe; Daniel F Simola; Karl J Staples; Ruby Sung; Ruth Tal-Singer; Andrew C Tuck; Stephanie Van Horn; Vincent Weynants; Nicholas P Williams; Jeanne-Marie Devaster; Tom M A Wilkinson
Journal:  Thorax       Date:  2018-01-31       Impact factor: 9.139

View more
  1 in total

1.  Variation of volatile organic compound levels within ambient room air and its impact upon the standardisation of breath sampling.

Authors:  Michael Jonathan Hewitt; Ilaria Belluomo; Simone Zuffa; Piers R Boshier; Antonis Myridakis
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.